Metastatic Esophageal Carcinoma Recruiting Phase 1 / 2 Trials for Lexatumumab (DB06599)

IndicationStatusPhase
DBCOND0120548 (Metastatic Esophageal Carcinoma)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03008278Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by SurgeryTreatment